NWBO

Northwest Biotherapeutics, Inc. Press Releases

$5.88
*  
0.18
 negative 
3.16%
Get NWBO Alerts
*Delayed - data as of Apr. 17, 2014 
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

NW BIO CLOSES ON FIRST $15 MILLION OF FINANCING FOR SUBSTANTIAL EXPANSION OF EUROPEAN PRODUCTION CAPACITY
4/15/2014 1:11:00 PM - PR Newswire

NW BIO ANNOUNCES FINANCING OF UP TO $32 MILLION
4/10/2014 8:15:00 AM - PR Newswire

NW BIO AGAIN SETS FEUERSTEIN RECORD STRAIGHT
4/7/2014 8:15:00 AM - PR Newswire

NW BIO REFUTES FURTHER FALSE AND MISLEADING CLAIMS BY FEUERSTEIN
3/28/2014 1:03:00 PM - PR Newswire

Technical Insight on Top Gainers -- Research on Signet Jewelers, Quicksilver Resources, Northwest Biotherapeutics, and Goodrich Petroleum
3/28/2014 11:00:00 AM - PR Newswire

Northwest Biotherapeutics To Present At The 4th Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference
3/27/2014 8:15:00 AM - PR Newswire

Approvals, Clinical Trial Results, Stock Summaries, Data Publication and Conference Participation - Analyst Notes on Northwest, La Jolla Pharma, Merrimack Pharma, Rosetta, and IntelliPharmaCeutics
3/13/2014 8:20:00 AM - PR Newswire

NW Bio Refutes False Claims By Adam Feuerstein
3/12/2014 9:59:00 AM - PR Newswire

NW Bio Announces Two German Approvals: "Hospital Exemption" for Early Access Program with DCVax-L and Eligibility of DCVax-L for Reimbursement
3/10/2014 8:00:00 AM - PR Newswire

NW Bio Receives Recommendation To Continue With Phase III GBM Brain Cancer Trial Based On Data Safety Monitoring Board's Safety Review
3/7/2014 8:00:00 AM - PR Newswire

NW Bio to Present at BIO CEO and Investor Conference 2014
2/6/2014 8:15:00 AM - PR Newswire

NW Bio Enters Into Agreements For Large-Scale Expansion Of Product Manufacturing, Handling And Distribution
1/27/2014 8:16:00 AM - PR Newswire

NW Bio to Present at Phacilitate's Washington Bioleaders' Immunotherapy 2014 Forum
1/27/2014 8:15:00 AM - PR Newswire

Mentor Capital Cancer Immunotherapy Index Up 97% in 2013
1/21/2014 11:01:00 AM - Business Wire